title: Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost-effectiveness.
abstract: The aim of this prospective, randomized trial was to compare the clinical results and the cost-effectiveness of urinary FSH (uFSH) and recombinant FSH (rFSH) in ovarian stimulation for intrauterine insemination (IUI) cycles in polycystic ovary syndrome (PCOS) patients. One-hundred and seventy PCOS infertile patients undergoing IUI were enrolled, and protocols of ovarian stimulation with uFSH or rFSH were randomly assigned. The total number of cycles performed was 379 (182 and 197, respectively). The main outcome measures were the number of mature follicles, the days of stimulation, the number of ampoules and IU used per cycle, the biochemical/clinical pregnancy rates, the number of multiple pregnancies and the cost-effectiveness. No statistically significant differences were found in the follicular development, length of stimulation, pregnancy rates, delivery rates and multiple pregnancies between the two groups. In the uFSH group, the cost per cycle remained significantly lower (218.51 +/- 88.69 versus 312.22 +/- 118.12; P < 0.0001), even though a significantly higher number of IU of gonadotrophins were used (809.3 +/- 271.9 versus 589.1 +/- 244.7; P < 0.0001). The cost-effectiveness (i. e. within a group, the total cost of all cycles divided by no. of clinical pregnancies) was 1729.08 in the uFSH group and 3075.37 in the rFSH group. In conclusion, uFSH and rFSH demonstrated the same effectiveness in ovarian stimulation in IUI cycles in PCOS patients. The urinary preparation is more cost-effective due to the difference of its cost per IU.
authors.affiliation: Centre of Reproductive and Perinatal Medicine, Department of Gynecological, Obstetrical and Pediatric Sciences, University of Perugia, Italy. gerber@unipg.it
authors.forename: Sandro
authors.initials: S
authors.lastname: Gerli
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Casini
authors.forename: Vittorio
authors.initials: V
authors.lastname: Unfer
authors.forename: Loredana
authors.initials: L
authors.lastname: Costabile
authors.forename: Marcella
authors.initials: M
authors.lastname: Mignosa
authors.forename: Gian Carlo
authors.initials: GC
authors.lastname: Di Renzo
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000191:economics* / Q000652:urine; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000191:economics; D010062:Ovulation Induction / Q000191:economics / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000191:economics; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000191:economics*
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone